Peptilogics is a clinical-stage biotechnology company focused on creating a new class of surgical therapeutics to address infections associated with implanted orthopedic hardware. Its lead candidate, zaloganan (PLG0206), rapidly penetrates biofilms to eradicate bacteria that standard antibiotics cannot reach and is the first drug specifically aimed at prosthetic joint infections (PJI). In a Phase 1b study, 13 of 14 patients (93%) remained infection-free 12 months after treatment, prompting the company to advance into a 240-patient Phase 2/3 pivotal trial scheduled to begin in December 2025. Zaloganan has secured QIDP, Orphan Drug, and Fast Track designations from the FDA, affording potential regulatory and market exclusivity advantages. The medical need is large: roughly 45,000 U.S. PJI cases occur annually, each costing health systems up to $390,000, and current surgical approaches fail up to half the time. Peptilogics has raised approximately $120 million in equity funding to date, in addition to significant non-dilutive grants from CARB-X, to finance its clinical and commercial plans.

Total raised

$121M

Funding rounds

4

Latest round

Series B

Latest activity

Oct 2025